Investors

Since 2004, AmpliMed has raised a total of $29.3 million which has been used to conduct seven clinical trials involving over 300 cancer patients:

• 2007 Series C for $5.1 million
• 2006 Series B for $14.6 million
• 2004 Series A for $9.6 million

Our current investors include:

• Valley Ventures III LP (Scottsdale/Tucson)
• Biotech Insight Management (Pebble Beach, CA)
• InvestBio (New York)
• Solstice Capital (Tucson/Boston)
• Village Ventures (Denver, CO)

The company's efforts are currently concentrated on the clinical development of its lead anti-cancer compound Amplimexon, which is in Phase II clinical trials.

Publications: Concerning Amplimexon® and Amplizone™

A newsletter concerning recent events at AmpliMed is available.